Zahra Ghiassi-Nejad

Zahra Ghiassi-Nejad

Auto-generated profile, based on publicly available information

Zahra Ghiassi-Nejad

Department of Radiation Oncology, Mount Sinai Hospital, New York, NY

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
ZGZahra Ghiassi-Nejad
Zahra Ghiassi-Nejad
MRMeng Ru
Meng Ru
EMErin Moshier
Erin Moshier
SCSanders Chang
Sanders Chang
SJSundar Jagannath
Sundar Jagannath
KDKavita Dharmarajan
Kavita Dharmarajan

1 May 2019 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
LSLucas Resende Salgado
Lucas Resende Salgado
SCSanders Chang
Sanders Chang
MRMeng Ru
Meng Ru
EMErin Moshier
Erin Moshier
ZGZahra Ghiassi-Nejad
Zahra Ghiassi-Nejad
KDKavita Dharmarajan
Kavita Dharmarajan

1 October 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
MCM. Chadha
M. Chadha
ZGZ. Ghiassi-Nejad
Z. Ghiassi-Nejad
SCS. Cate
S. Cate
AGA. Gillego
A. Gillego
JWJ. Wallach
J. Wallach
SBS.K. Boolbol
S.K. Boolbol
Purpose/Objective(s) Local-regional therapy in BC is largely guided by clinico-pathologic features, whereas molecular biology and intrinsic gene signatures of the cancer are used to prescribe risk-tailored systemic therapy. The objective of this study was to evaluate the incidence of local-regional relapse in early stage BC. Further, to evaluate the correlation of Oncotype Dx score, in addition to the clinico-pathologic features with risk of relapse. Materials/Methods This was an institutional review board approved retrospective study from our institutional database. We identified 1355 patients with ER+ Stage I and II BC who had undergone Oncotype Dx testing. For this study, we included only those patients with unilateral BC and minimum follow-up of 2 years (n = 792). Patients were treated with mastectomy, or lumpectomy and radiation (RT) + systemic therapy at the discretion of treating physician. We scored patients based on the first site of failure: local-regional relapse (LRR) only, distant metastases (DM) only, and both (LRR+DM). The association between clinical covariates (Age: ≥50, 2 cm; Grade), Oncotype Dx score (<18, ≥18), local treatment (mastectomy vs. lumpectomy/RT), and failure events was evaluated by univariable and multivariable Cox proportional hazards models. Survival was estimated using the Kaplan-Meier and log-rank test method. Results Tabled 1 Abstract 116; Table 1 Factors Influencing LRR and DM on multivariate analysis Risk Factors Local-regional relapse Hazard Ratio Distant Metastasis Hazard Ratio T-size >2 cm 2.77 (95% CI = 1.07-7.15; P = 0.034)* 6.7 (95% CI 2.8-16.3; P<0.0001)* Oncotype Score ≥18 2.8 (95% CI = 1.08-7.36; P = 0.03)* 5.2 (95% CI 1.7-15.5; P = 0.003)* Open table in a new tab Conclusion Our study suggests that in addition to clinicopathologic variables Oncotype Dx score may provide useful information regarding risk of LRR. Further research is needed to establish a role for molecular and gene profiles in providing risk-tailored delivery of radiation. Acknowledgment Grant support by Ellen Blair Research Fund.